Cochlear Limited (ASX:COH) has met analysts’ expectations to book a record full year profit, lifting 16 per cent to $180.1 million.
In the 2011 financial year revenue rose 10 per cent to $809.6 million, another record result for the company.
The hearing implant manufacturer’s result was aided by the launch of its Nucleus 5 bionic ear.
The recall of a competing implant from one of its rivals in the year, is also understood to have boosted sales.
Looking ahead, Cochlear says it remains positive and well positioned to meet increased demand for its products in developed and emerging markets.
A final dividend of $1.20 per share has been declared, 70 per cent franked and up 14 per cent from 2010.
